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Abstract: BACKGROUND DNA methylation is a highly studied epigenetic signature that is associated
with regulation of gene expression, whereby genes with high levels of promoter methylation are generally
repressed. Genomic imprinting occurs when one of the parental alleles is methylated, i.e., when there is
inherited allele-specific methylation (ASM). A special case of imprinting occurs during X chromosome
inactivation in females, where one of the two X chromosomes is silenced, to achieve dosage compensation
between the sexes. Another more widespread form of ASM is sequence dependent (SD-ASM), where
ASM is linked to a nearby heterozygous single nucleotide polymorphism (SNP). RESULTS We developed
a method to screen for genomic regions that exhibit loss or gain of ASM in samples from two conditions
(treatments, diseases, etc.). The method relies on the availability of bisulfite sequencing data from
multiple samples of the two conditions. We leverage other established computational methods to screen
for these regions within a new R package called DAMEfinder. It calculates an ASM score for all CpG
sites or pairs in the genome of each sample, and then quantifies the change in ASM between conditions.
It then clusters nearby CpG sites with consistent change into regions. In the absence of SNP information,
our method relies only on reads to quantify ASM. This novel ASM score compares favorably to current
methods that also screen for ASM. Not only does it easily discern between imprinted and non-imprinted
regions, but also females from males based on X chromosome inactivation. We also applied DAMEfinder
to a colorectal cancer dataset and observed that colorectal cancer subtypes are distinguishable according
to their ASM signature. We also re-discover known cases of loss of imprinting. CONCLUSION We have
designed DAMEfinder to detect regions of differential ASM (DAMEs), which is a more refined definition
of differential methylation, and can therefore help in breaking down the complexity of DNA methylation
and its influence in development and disease.
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METHODOLOGY
DAMEfinder: a method to detect differential 
allele-specific methylation
Stephany Orjuela1,2, Dania Machlab3, Mirco Menigatti2, Giancarlo Marra2 and Mark D. Robinson1* 
Abstract 
Background: DNA methylation is a highly studied epigenetic signature that is associated with regulation of gene 
expression, whereby genes with high levels of promoter methylation are generally repressed. Genomic imprinting 
occurs when one of the parental alleles is methylated, i.e., when there is inherited allele-specific methylation (ASM). 
A special case of imprinting occurs during X chromosome inactivation in females, where one of the two X chromo-
somes is silenced, to achieve dosage compensation between the sexes. Another more widespread form of ASM is 
sequence dependent (SD-ASM), where ASM is linked to a nearby heterozygous single nucleotide polymorphism 
(SNP).
Results: We developed a method to screen for genomic regions that exhibit loss or gain of ASM in samples from two 
conditions (treatments, diseases, etc.). The method relies on the availability of bisulfite sequencing data from multiple 
samples of the two conditions. We leverage other established computational methods to screen for these regions 
within a new R package called DAMEfinder. It calculates an ASM score for all CpG sites or pairs in the genome of each 
sample, and then quantifies the change in ASM between conditions. It then clusters nearby CpG sites with consistent 
change into regions. In the absence of SNP information, our method relies only on reads to quantify ASM. This novel 
ASM score compares favorably to current methods that also screen for ASM. Not only does it easily discern between 
imprinted and non-imprinted regions, but also females from males based on X chromosome inactivation. We also 
applied DAMEfinder to a colorectal cancer dataset and observed that colorectal cancer subtypes are distinguishable 
according to their ASM signature. We also re-discover known cases of loss of imprinting.
Conclusion: We have designed DAMEfinder to detect regions of differential ASM (DAMEs), which is a more refined 
definition of differential methylation, and can therefore help in breaking down the complexity of DNA methylation 
and its influence in development and disease.
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Background
Epigenetic modifications refer to mitotically herit-
able, chemical variations in DNA and chromatin in the 
absence of changes in the DNA nucleotide sequence 
itself [1, 2]. Although there are a large number of such 
documented phenomena, DNA methylation (i.e., methyl 
groups added to cytosines in mammalian DNA, mostly in 
CpG dinucleotides) stands out because the mechanism of 
heritability, via maintenance methyltransferases, is well-
determined [3–5]. In addition, due to well-known effects 
of chemical reactions, such as sodium bisulfite conver-
sion of cytosines to uracils [6], and biochemical reactions 
like TET-pyridine borane conversion of 5-methylcytosine 
to dihydrouracil [7], the interrogation of DNA methyla-
tion level across the genome can be sampled and quanti-
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DNA methylation plays a role in several biological phe-
nomena. It is believed to be associated with gene expres-
sion, with the canonical relationship suggesting that 
transcriptional units with high levels of promoter meth-
ylation are repressed or silenced, although not all genes 
with unmethylated promoters are switched on, since 
other epigenetic mechanisms of silencing may come into 
play [8].
Genomic imprinting, where genes are expressed in a 
parent-of-origin manner [9], is also regulated by DNA 
methylation. Imprinting occurs via allele-specific meth-
ylation (ASM), in which only the paternal or the mater-
nal allele is methylated in all or most of the tissues of an 
individual [9]. This methylation asymmetry is conferred 
during gametogenesis in the parental germlines, or dur-
ing early embryogenesis after fertilization, and will 
remain during the lifetime of the offspring [10]. A recent 
survey [11] reported 228 genes linked to imprinted con-
trol, and from those, 115 linked to imprinted regulation 
in human placenta. These genes are known for their roles 
in embryonic and fetal development, placental formation, 
cell growth and differentiation, metabolism and circa-
dian clock regulation [11]. In fact, loss of imprinting and 
abnormal expression of imprinted genes are implicated 
in severe congenital diseases, like the neurodevelop-
ment disorders Angelman and Prader–Willi syndromes. 
The first is caused by the lack of maternal UBE3A gene 
expression, and the second by loss of paternal expression 
of several contiguous genes on chromosome 15q11–q13 
[12]. Furthermore, disruption of imprinting in somatic 
cells has been implicated in the pathogenesis of differ-
ent cancers, like loss of imprinting within the H19/IGF2 
imprinting control region in colorectal cancer [13], and 
gain of imprinting at 11p15 in hepatocellular carcinoma 
[14].
A special and well-characterized case of imprinting 
occurs during X chromosome inactivation (XCI), where 
one of the two X chromosomes is randomly silenced via 
DNA methylation and other epigenetic mechanisms, 
early in development in each cell of a female, to achieve 
dosage compensation between the sexes [15].
Beside imprinting and XCI, the rest of the genome is 
thought to be symmetrically methylated across both 
alleles. However, sequence-dependent ASM (SD-ASM) 
has been frequently reported in the last 10 years and 
appears to be widespread in the human genome [16–21]. 
In this case, the DNA methylation asymmetry between 
the parental alleles appears to be causally related to the 
presence of a single nucleotide polymorphism (SNP). As 
for imprinted ASM and XCI, SD-ASM can be associated 
with silencing of one of the two parental gene copies, 
likely mediated by cis-acting, allele-specific changes in 
affinity of DNA-binding proteins [21]. SD-ASM appears 
to be tissue-specific [22, 23], thus it is commonly believed 
that the interaction between genetic variants (i.e., SNPs) 
and epigenetic mechanisms (i.e., effects of DNA meth-
ylation asymmetry on gene expression) modulate the 
susceptibility of the general population to frequent, 
multi-factorial diseases affecting specific organs. An 
example of this is SD-ASM in the PEAR1 intron 1, which 
is linked to platelet reactivity and cardiovascular dis-
ease [24]. Another example is SD-ASM in FKBP5, a gene 
encoding a cochaperone of the glucocorticoid receptor 
with a potential role in the stress hormone-regulating 
hypothalamic–pituitary–adrenal axis [25], which poses 
an increased risk to stress-related psychiatric disorders in 
individuals who suffered an abuse during childhood [26]. 
Although the modulation of the susceptibility to a com-
plex disease by SD-ASM is generally weak and influenced 
by environmental factors, it is worth noting that 5–10% 
of all SNPs might be associated with SD-ASMs in the 
genome of a given tissue of a given individual [19, 20, 27].
Although there are several technologies to study DNA 
methylation, such as microarrays that genotype bisulfite-
converted DNA, or lower resolution capture technolo-
gies such as methyl-binding domain (MBD) sequencing 
[28], or methylated DNA immunoprecipitation (MeDIP) 
sequencing [29], bisulfite sequencing (BS-seq) remains 
distinct for the ability to read out DNA methylation of a 
single allele at base-resolution. Importantly, BS-seq can 
be conducted both in an unbiased genome-wide fash-
ion, or in combination with technologies that focus the 
sequencing to particular regions, either by making use of 
hybridization or by enzyme digestions [30].
Recent studies have obtained ASM readouts from 
mapped bisulfite reads, by assigning them to the alleles 
of each known heterozygous SNP. Methylation levels 
are then determined for all allele-linked cytosines in the 
reads (see [20, 31, 32] for recent examples). The ASM cal-
culated in this way is interpreted as SD-ASM, and it does 
not include imprinted ASM nor XCI, since they are not 
necessarily sequence dependent. Calculating ASM in this 
fashion is limited by the availability of SNP information 
from either DNA-seq or SNP-array data, or directly from 
the BS-seq reads [33]. However, performing different 
types of high-throughput experiments is economically 
restrictive and time consuming, and deriving SNPs from 
BS-seq reads can be problematic due to bisulfite conver-
sion of DNA (i.e., distinguishing a C/T SNP from a C/T 
conversion of a methylated cytosine) and imbalanced 
strand coverage (i.e., when the Watson and Crick strands 
are not equally or highly covered) [33].
Considering these limitations in ASM detection, a cou-
ple of studies have sought to make sole use of BS-seq 
reads to screen for the full spectrum of ASM. The tools 
allelicmeth and amrfinder (from the same authors) [34] 
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are the only available executable methods that detect 
ASM without SNP information. In brief, the allelicmeth 
method creates a contingency table with the counts of 
methylated and unmethylated reads covering a pair of 
CpG sites. A score is calculated via Fisher’s exact test 
that represents the probability that both CpG sites have 
an equal proportion of methylated–unmethylated reads. 
amrfinder also calculates ASM but at a regional level. It 
fits two statistical models, one assuming that both alleles 
are equally methylated, and the other assuming different 
methylation states for the two alleles. A region is consid-
ered to have ASM by comparing the likelihoods of the 
two models. A more recent algorithm termed Methyl-
Mosaic relies on the principle that bimodal methylation 
patterns, independent from the genotype, are a good 
indicator of ASM [35]; however, to our knowledge there 
is no publicly available implementation.
Based on the current state of ASM detection from BS-
seq reads, we set out to develop a simple yet effective 
method to screen for genomic regions that exhibit loss or 
gain of ASM between samples from distinct conditions. 
The methods mentioned above detect ASM in individual 
samples; however, they do not allow a flexible compari-
son between groups of samples, such as that performed 
in a typical differential methylation analysis [36, 37], 
where the goal is to find the effect of treatments or dis-
eases on methylation, reflected as increase or decrease 
of methylation levels. Here, we are interested in per-
forming such differential analysis but focusing on the 
effect of ASM, reflected as gain or loss of allele specific-
ity. For this task, we introduce DAMEfinder (Differential 
Allele-specific MEthylation finder), an R package [38] 
that consists of (i) a scoring function that reflects ASM 
for several samples; (ii) integration with limma [39] and 
bumphunter [40] to detect differentially allele-specific 
methylated regions (DAMEs); and (iii) accurate estima-
tion of false discovery rates (FDR). We demonstrate the 
ASM score and DAMEfinder on two real datasets, one 
based on targeted enrichment BS-seq, comparing nor-
mal colonic mucosa to cancerous colorectal lesions, and 
another on whole genome BS-seq (WGBS), comparing 
blood monocytes from healthy females and males.
Results
The overall DAMEfinder workflow
Figure 1 gives an overview of the pipeline. We make con-
siderable use of existing tools and keep inputs/outputs in 
standard formats. To make use of the package, the user 
must independently use bismark to map paired-end BS-
seq reads against a reference genome (Fig. 1a). Once this 
is done, the user has the option to detect ASM for each 
sample in two ways: (1) using the output from methtuple 
[41], which computes read counts of pairs of nearby CpG 
sites. From these counts, we compute an ASM score; 
(2) using an additional VCF file containing heterozy-
gous SNPs. For each SNP we call methylation from the 
reads containing that SNP, and calculate an ASM score 
for each CpG site (Fig.  1b and details). From the set of 
scores, we leverage routines from the bumphunter and 
limma packages to calculate a statistic and detect regions 
showing persistent change in ASM. We call these regions 
DAMEs (Fig.  1c). We estimate and control a regional 




The most straightforward way of detecting SD-ASM 
from mapped reads is by assigning them to either of the 
alleles at each known heterozygous SNP. Methylation 
status is then determined for each allele-linked cytosine 
in the reads. We have used this strategy to calculate 
an SNP-based ASM score ( ASMisnp ), and considered it 
to be the genuine form of SD-ASM, since it is derived 
from an extra layer of information, i.e., the genotype of 
an individual.
Ideally, the genotype should originate from genome 
sequencing; however, this type of data is scarce in large 
cohorts of samples. Therefore, we have employed Bis-
SNP [33] to call SNPs directly from the BS-seq reads. 
The method uses Bayesian methods to infer strand-
specific base calls, with SNP population frequencies as 
prior probabilities.
We extract the reads overlapping every heterozygous 
SNP in a VCF file with the GenomicAlignments R pack-
age [44], and for each read determine the methylation 
status of the CpG sites. Sites that are not in reads con-
taining an SNP are not considered. We calculate ASMisnp 
for each CpG site i contained in the reads of an SNP as
where X ir
M
 and X ia
M
 correspond to the number of methyl-
ated reads from the reference r allele, and the alternative 
a allele. In practice, it makes no difference which allele is 
the reference or the alternative. X ir and X ia correspond 
to the total number of reads covering the reference and 
the alternative allele (see schematic diagram in Fig. 1b). 
The score ranges from 0 to 1, where a score of 1 repre-
sents the scenario where one allele is completely methyl-
ated, and the other allele is fully unmethylated; a value of 
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Tuple‑based ASM
Instead of restricting ASM detection to allele-linked 
reads, we can make use of an entire set of CpG sites to 
screen for different types of ASM. For this task, we 
designed a score under the assumption that pairs of CpG 
sites in the same DNA molecule (read) are correlated [45, 
46], and that in a biallelic organism, intermediate levels 
of methylation could represent allele specificity, i.e., the 
proportion of methylated reads in a pair of CpG sites or 
tuple is close to 0.5. We make this assumption knowing 
that other scenarios exist in which intermediate methyla-
tion can occur (e.g., cellular heterogeneity). Therefore, we 
consider this score only as a proxy for ASM.
We calculate the score as a weighted log-odds ratio:
Fig. 1 The DAMEfinder pipeline. a Files necessary to run DAMEfinder are reported in yellow rectangles. White rectangles show the main R outputs 
from DAMEfinder. Steps to be run before DAMEfinder are in the circle, i.e., fastq files undergo quality control and read alignment with bismark 
[43]. The resulting bam file is used to calculate an ASM score, which can be done in two ways: b (i) the tuple-based strategy that takes as input a 
beforehand created methtuple [41] file. The score is calculated based on the read counts of pairs of CpG sites. (ii) the SNP-based strategy, which 
takes as input both the bam file and a VCF file with heterozygous SNPs. Here, the score is calculated for each CpG site in the reads containing a 
SNP. c We determine differential ASM by calculating a statistic based on either the tuple ASM or the SNP-ASM (using limma [39]), which reflects the 
difference between two conditions (Group A vs. Group B) for each genomic position (tuple or site). DAMEs are defined based on this statistic, as 
regions of contiguous positions with a consistent change in ASM
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where X i
·
 corresponds to the number of reads covering 
a unique pair of CpG sites i, generated by running the 
methtuple tool. CpG sites in a pair can be methylated 
MM, unmethylated UU, or mixed (UM or MU). A con-
stant c is added to every X i to avoid dividing by 0. The 
log-odds ratio is multiplied by a weight, wi , which is set 
such that the ratio of MM:UU can depart somewhat from 
a 50:50 relation, while MM or UU tuples, which repre-
sent absence of allele specificity, are attenuated to 0. This 
is calculated as
where ǫ represents the degree of allowed departure from 
a 50:50 ratio (i.e., 0.5), and θ i:
represents the moderated proportion of MM to MM 
+ UU reads. It is based on a beta model, where γ is a 
hyperparameter set to penalize fully methylated or fully 
unmethylated tuples, i.e., when the MM:UU balance goes 
farther from a 50:50 relation. In Fig. 2, we show 4 exam-
ples in which the score is calculated with and without wi . 
According to our assumption, example 1 is the best case 
of ASM (Fig. 2a), yet we see for example, that examples 1 
and 3 have the same absolute log-odds ratio (without wi ), 
but imposing the weight reduces the score in example 3 
below that of example 1 (Fig.  2c). We also demonstrate 
how the ASMtuple score is affected by the tuning of ǫ and γ 
(Additional file 1: Figure S13A, B). ǫ has the most impact 
in the score, i.e., smaller departures from 50:50 result in 
lower values of ASMituple , whereas only very large values 
of γ (e.g. > 5) influence the distribution of ASMituple.
ASM score validation
SD‑ASM
To test the ASMtuple score, we used the ASMsnp score 
as an indicator of true SD-ASM, and calculated the 
ASMtuple score, the allelicmeth and amrfinder scores, 
and a score representing absolute deviation from 50% 
methylation (methdeviation; see “Methods”), in a single 
normal tissue sample from the colorectal cancer (CRC) 
dataset (see “Methods”). We set CpG tuples with ASMsnp 
above specific thresholds (0.5 and 0.8) to be true SD-
ASM. These resulted in 1284 and 69 CpG tuples with SD-
ASM, respectively, which corresponded to 0.069% and 
0.003% of all the tuples scanned in this sample.
Figure 3 shows the true-positive rate (TPR) and false-
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at different CpG tuples classified in 3 different coverage 
thresholds (left to right). Two ASMsnp cutoffs (top to bot-
tom) were chosen as the truth. ASMtuple was consistently 
more sensitive and specific than the other three scores, 
especially as coverage increased. Intermediate meth-
ylation values yielded comparable results; however, the 
ASMtuple was able to detect more cases of “real” ASM in 
all combinations. allelicmeth increasingly failed as cov-
erage and ASMsnp value increased. amrfinder performed 
better than allelicmeth at higher true values. The dis-
tributions of the scores from each facet in Fig.  3 are in 
Additional file 1: Figures S11A, B and S12A–D.
Chromosome X inactivation
As an additional validation of the ASMtuple score, we 
used the blood dataset (see “Methods”) to compare 
healthy male and female samples. In principle, females 
should exhibit allele specificity in the X chromosome due 
to XCI and thus higher ASMtuple values. Figure 4 shows 
the distribution of ASMtuple values across all samples in 
the dataset, in chromosome 3 and chromosome X. From 
a whole genome perspective (Fig.  4a), there is little dif-
ference between males and females in X chromosome 
(mean of sample-means females: 0.13, males: 0.098), and 
practically no difference in chromosome 3 (0.060, 0.074). 
However, by focusing on CpG tuples located in promoter 
regions (1 kb upstream the transcription start site—TSS), 
we observed ASM values increased only in chromosome 
X of females (Fig. 4b; 0.30, 0.088).
Imprinted ASM
In the same blood dataset, we also compared the 
ASMtuple scores from the promoters of imprinted genes 
reported in [11] (see “Methods”) to the scores from 
the rest of the genome (Fig. 4c). As expected, ASM scores 
were higher in the tuples located within imprinted pro-
moters, for both males and females.
DAME detection
As depicted in Fig.  1, after calculating ASMtuple or 
ASMsnp in the DAMEfinder pipeline, we continue to 
detect regions of persistent change in ASM between one 
condition to another within a cohort of samples. Change 
can occur as loss of ASM, when a reference group exhib-
its allele specificity across a region (high values of ASM), 
and the group of interest has this same region fully meth-
ylated, unmethylated, or with random methylation (low 
values of ASM). Change can also occur as gain of ASM, 
where the reference group does not have allele specificity 
and the group of interest does. We call regions such as 
this DAMEs (Differentially Allele-specifically MEthylated 
regions).
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Fig. 2 ASMtuple weighting strategy. We show 4 examples of read-patterns in a single tuple. a All cases have 8 reads covering a single tuple. Example 
1 has X i
MM
 and X i
UU
= 4 , and X i
UM
 , X i
MU
= 0 . Example 2 X i
MM
= 8 , the rest of combinations 0. Example 3 X i
UM
 , X i
MU
= 4 , and example 4 X i
UU
 , X i
UM
= 4 . 
b Probability density function (PDF) for each Beta(γ + X iMM , γ + X
i
UU) of the 4 examples, when γ = 0.5 . Pink-shaded area corresponds to 0.5 ± ǫ , 
when ǫ = 0.2 . c Based on the PDF, we calculate the log-odds ratio (top), and the log-odds ratio multiplied by wi (bottom)
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To detect DAMEs, we first obtain a regression coef-
ficient βij followed by a t-statistic using the R pack-
age limma [39] (see “Methods”), on the transformed 
ASMituple score, or on the ASM
i
snp score, for each CpG 
position i (tuple or site), across j samples (see “Methods” 
for model).
We detect regions of contiguous CpG positions where 
βij persistently deviates in the same direction from zero; 
this is done in two ways:
Permuting bumphunted regions
The regionFinder function from bumphunter is used to 
scan for regions (R) where CpG sites close in proximity 
have βij above a user-defined threshold K, which corre-
sponds to a percentile of βij . For each region detected, the 
function also calculates an area A =
∑
iǫR |βij| . For the 
CRC dataset, we used the default value K = 0.7 , and dis-
tance between CpG positions up to 100 bp.
We assess significance of every region detected by 
assigning an empirical p value. For every non-redundant 
permutation of the coefficient of interest (chosen from a 
column in the design matrix X), regionFinder is applied 
again. All the areas generated by all permutations are 
pooled to generate a null distribution of areas [47]. We 
define the p values for each R as the proportion of null 
areas greater than the observed A; p values are adjusted 
using the Benjamini–Hochberg method [48] from the 
stats R package [38].
Cluster‑wise correction
Optionally, we define regions that exhibit changes in 
ASM by first generating clusters of CpG sites with clus-
terMaker. For each cluster, we aggregate all the CpG 
position p values generated by limma using the Simes 
method [42], which is applicable when test statistics 
exhibit positive dependence [49]. As implemented in 
[50], we calculate
where p(1), . . . , p(n) are the ordered p values of each CpG 
position i in a cluster c, and n is the number of CpG posi-
tions in the cluster. pc summarizes evidence against the 
null hypothesis that all CpG positions are not differential. 
We adjust pc as above.
Evaluation of DAME detection
We compared the different strategies to control FDR 
in the DAME detection pipeline, by applying them to a 
semi-simulated dataset and plotting the TPR and FDR 
(5)pc = min{np(i)/(i)}
Fig. 3 Comparison of the ASMtuple score to allelicmeth, amrfinder and methylation deviation, by considering ASMsnp as true ASM. We calculated 
ASMtuple scores (red), deviations from 50% methylation (blue), allelicmeth scores (green), amrfinder scores (purple) in a sample of normal 
colorectal mucosa included in the CRC dataset. The scores were compared to each other by plotting the FPR against the TPR achieved. The plots are 
drawn for different intervals of read coverage (5–9, 10–49, ≥ 50), and different levels of the ASMsnp score ( ≥ 0.5, ≥ 0.8), which is considered the “true” 
ASM. Overall AUCs (area under the curve) for the top three panels: ASMtuple = 0.83, deviations from 50% = 0.81, allelicmeth = 0.66, amrfinder = 
0.68. Overall AUCs for the lower three panels: ASMtuple = 0.82, deviations from 50% = 0.81, allelicmeth = 0.64, amrfinder = 0.72
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Fig. 4 ASMtuple distribution in the genome. We used XCI as a proof of concept for allele specificity in females. Data from the blood dataset 
comprising 3 females and 3 males were used for this analysis. a When considering all CpG tuples in the genome, the ASMtuple distribution (y-axis) in 
chromosome 3 and chromosome X is similar in both genders. b When considering CpG tuples located in promoter regions (i.e., 1 kb upstream of 
the TSS), the ASMtuple score is higher in chromosome X of females. c Promoter regions of 89 known imprinted regions (see “Methods”) also exhibit 
higher ASMtuple compared to values in the rest of the genome. Y-axis in all plots is square-root transformed
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achieved at different adjusted p value thresholds (0.01, 
0.05, 0.1) (Fig.  5). We designed a small set of simulated 
DAMEs to evaluate the FDR control of the above strate-
gies. We took 6 samples of normal tissue from the CRC 
dataset and calculated ASMsnp scores in each of them. 
We assumed these scores to be the ASMsnp baseline in 
the simulation. Then, we divided the samples into two 
groups of three samples each, and for all the CpG sites 
covered by the 6 samples, we defined clusters of con-
tiguous CpG sites. For each truly differential cluster, we 
added signal to a randomly determined subset of adja-
cent CpG sites (see “Methods” for more details).
Overall, the empirical p value controlled the FDR, 
whereas the Simes method tended to be less conservative 
but more sensitive (Fig. 5 and Additional file 1: Figure S1 
for same plot tested with different parameters).
Discovery of DAMEs in colorectal cancer dataset
We used a previously published dataset comprising 6 
patients with diagnosed colorectal cancer, three with 
CIMP (CpG-Island Methylator Phenotype), and three 
without CIMP (see “Methods”); DNA from normal 
mucosa and cancer lesions was bisulfite-sequenced. We 
ran DAMEfinder on this dataset in both modes, there-
fore obtaining the ASMsnp and ASMtuple scores. After fil-
tering for coverage (more than 5 reads) and for sites with 
more than 80% of samples covered, we obtained infor-
mation for 43,420 CpG sites using the ASMsnp . Using 
the tuple score, we obtained summaries for 1,849,831 
CpG pairs. Within the DAMEfinder pipeline, we gener-
ated multi-dimensional scaling (MDS) plots using each 
score (Fig. 6a, b), and observed that both scores are able 
to recover distinct CRC phenotypes. However using the 
ASMtuple score, samples cluster according to tissue type 
(normals, CIMP cancer and non-CIMP cancer) (Fig. 6a), 
whereas using the ASMsnp score, only the two cancer 
Fig. 5 FDR control of p value assignment strategies. We plot the FDR against the TPR achieved by the two alternatives for assigning p values to 
a DAME: the first by generating permutations and setting a threshold K (see text) on the t-statistic (here 0.2, 0.5, 0.8), the second using the Simes 
method. Lines are colored by strategy. Each strategy was run 50 times with the same simulation parameters. Colored circles indicate that the FDR 
achieved is smaller than the specified threshold (dashed lines at 0.01, 0.05 and 0.1), and white circles indicate the opposite. x-axis is square-root 
transformed
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Fig. 6 ASM scores on the CRC dataset. a MDS plot of all the samples in the CRC dataset, based on all the the ASMtuple scores. Scores were 
square-root transformed before plotting. b MDS plot based on the ASMsnp scores. Scores were arcsine transformed. MDS plots were generated with 
the plotMDS function from limma and the top 1000 most variable positions. N: normal mucosa; C: CRC. Each pair of samples from the 6 patients 
with CRC is numbered from 1 to 6. c A DAME detected in CIMP CRCs using the ASMtuple score shows a higher signal than using the ASMsnp score. 
Region shown is located on chr9:99,983,697–99,984,022, shaded region in the center corresponds to the DAME. Tracks for methylation levels (meth) 
and methylation levels in reference and alternative alleles (based on SNP in chr9:99,983,812) are also shown. Points in ASMtuple and meth tracks 
correspond to intermediate positions between a pair of CpG sites. Points in the rest of tracks correspond to CpG sites. d − log10(p values) at each 
CpG position, calculated with ASMtuple and ASMsnp . Black line is drawn at − log 10(0.05) . Sample 4 (C4 and N4) does not appear in the last two 
tracks because it is not heterozygous at the evaluated SNP
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types are distinguishable, while the normal tissues cluster 
with their matched cancers (Fig. 6b).
We screened for DAMEs comparing cancer to nor-
mal tissue, in CIMP and non-CIMP independently. 
Both SNP and tuple-based scores were calculated, and 
for each separately, DAMEs were detected using the 
Cluster-wise correction (Additional file  1: Figure S2 
for p values of both Cluster-wise correction and Per-
mutations). When using the ASMsnp score, we could 
not detect DAMEs with an adjusted p value below 
0.05. Using the ASMtuple score, we were able to detect 
4051 DAMEs in the CIMP samples (versus matched 
normal samples), and 258 in the non-CIMP samples. 
We noticed that regions detected using ASMtuple were 
also detected using ASMsnp , but with lower strength 
of signal and with p values above a cutoff of 0.05 (one 
example in Fig. 6c), and other regions showing contra-
dicting changes in ASM (one example in Additional 
file  1: Figures  S3, S4). Although the latter was rare 
(from all the 2219 DAMES detected in CIMP using 
ASMsnp , without a p value cutoff, only 0.36% disagreed 
on the ASM change), the cases we did find, overlapped 
tuple-DAMEs with the highest p values, e.g., regions 
at the bottom of the DAME list. In addition, we found 
DAMEs corresponding to known regions exhibit-
ing loss of imprinting in cancer, including those in the 
genes MEG3, H19, and GNAS [13, 51] (Fig. 7).
Considering the high number of DAMEs detected in 
the CIMP contrast compared to the non-CIMP contrast, 
we thought this could be a consequence of hypermeth-
ylation in CIMP [52], and so a typical DMR (differentially 
methylated region) analysis would be able to detect these 
same regions. To corroborate this, we performed a DMR 
analysis on the CIMP and non-CIMP contrasts using 
the dmrseq R package [47] (Additional file 1: Figure S5 
for top DAMEs and DMRs per comparison). We found 
that from the 6753 DMRs (5,040 hypermethylated, 1713 
hypomethylated) detected in the CIMP comparison, 
2285 overlap with DAMEs (hypermethylated DMRs = 
32%, hypomethylated DMRs = 1.7% from total DMRs), 
and from 13,220 DMRs in the non-CIMP comparison, 
only 164 overlap (hypermethylated DMRs = 0.57%, 
hypomethylated DMRs = 0.66%) (Table 1).
Because of this overlap, we conclude that a proportion 
(1146 [28%] in CIMP, 93 [36%] in non-CIMP) of DAMEs 
would not be detected via a typical DMR analysis. Fig-
ure 8 shows 4 examples of DAMEs missed by the DMR 
detection. In principle, these regions exhibit differential 
methylation according to the global methylation levels 
(bottom panels of each region); however, the hypermeth-
ylation reaches intermediate values, which might not 
represent a sufficiently high effect size to be detected. In 
the context of differential ASM, these intermediate values 
are highly scored, based also on the allele specificity of 
the change. Therefore, even though these are not highly 
ranked DAMEs, they were still detected as such.
Discussion
We have developed a scoring method that provides a 
measure of allele-specific methylation, and developed a 
method (DAMEfinder) that detects regions that display 
loss or gain of allele-specific methylation, by leveraging 
existing methods into a single framework. We offer the 
possibility to detect regions exhibiting ASM based on 
genotype information ( ASMsnp ), or independent from it 
( ASMtuple ). The latter offers a novel approach for iden-
tifying different types of ASM, such as imprinted, non-
imprinted, XCI, and new types yet to be described.
We have considered the ASMsnp score as genuine SD-
ASM, and calculated it using heterozygous SNPs. We 
employed Bis-SNP to extract the SNPs from the BS-seq 
reads. The methods’ accuracy (as occurs with normal 
SNP callers) requires a high read depth, because infor-
mation from both strands of DNA is necessary to infer 
if a cytosine has been bisulfite-converted or not. The 
authors of the tool found that heterozygous SNPs require 
a minimum of 10X coverage to be accurately called (80% 
sensitivity), and as depth is gradually increased to 30X, 
sensitivity reaches 100%. For our colorectal cancer analy-
sis we only used coverages above 10X, and observed that 
increasing coverages did not affect our ASMsnp score 
(Additional file 1: Figure S7D). We also observed that the 
ROC curves from Fig.  3 did not change in the last two 
coverage groups (10–49 and ≥ 50).
Regarding the performance of the SNP-independent 
scores (allelicmeth, deviations from 50% methyla-
tion and ASMtuple ), we observed that ASMtuple showed 
favorable performance at identifying individual cases 
of SD-ASM at sites with  different coverage levels. The 
scaled methylation also demonstrated high sensitivity 
and specificity, and as the true SD-ASM score ( ASMsnp ) 
and coverage increased, results were close to those of the 
ASMtuple score. Nonetheless, the advantage of using the 
ASMtuple score is the flexibility in its implementation; in 
specific, the weight that is added to the log-odd ratio can 
be easily adapted as described in “Methods”.
In contrast, the allelicmeth score reduced its perfor-
mance when the true ASM value was increased. As for 
amrfinder, we believe defining ASM as regional is a nice 
implementation in this method, and can make ASM 
interpretation and visualization easier. However, the defi-
nition of regions is done for each sample independently, 
and this does not allow for a direct comparison between 
samples. This is the main reason why our ASM scores are 
not regional. Our method focuses on obtaining regions of 
consistent change in ASM between conditions relative to 
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Fig. 7 DAMEs overlapping known loci exhibiting loss of imprinting in colorectal cancer. a DAME located in chr14:101,291,540–101,293,480, 
upstream the imprinted MEG3 gene. The loss of imprinting was significant in both types of CRCs. b DAME located in chr11:2,021,017–2,021,260, 
upstream the imprinted H19 gene. Loss of imprinting only occurred in CIMP CRCs. c DAME in the GNAS gene located in chr20:57,425,758–
57,428,036. Loss of imprinting was detected in both types of CRCs. Y-axis in all panels corresponds to ASMtuple means. Lines connect means at 
intermediate positions between a pair of CpG sites. Shared areas correspond to confidence intervals at each position (standard errors of the mean)
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the variability, which in turn implies consistent ASM in 
the majority of samples from an experimental condition.
Our ASMtuple score was able to distinguish female from 
male samples based on XCI, which we have considered 
as another case of true ASM. When analyzing the entire 
genome, we did not find differences between males and 
females. The fact that the entire female chromosome X 
does not contain high ASM, or that the global distribu-
tion of methylation is not skewed toward intermediate 
values has been shown before [53]. In addition, the pres-
ence of genes escaping XCI may also affect global ASM. It 
is known that 15% of genes escape XCI, and an additional 
10% varies in the inactivation state among the female 
population [54]. Therefore, a mixture of ASM scores in 
females is an accurate reflection of the complex dynamics 
of XCI.
We were also able to validate the score by compar-
ing the promoters of 89 known imprinted genes with 
the rest of the genome. We observed an increase in the 
ASM of imprinted genes, with a bimodal distribution of 
ASM scores. This can be a reflection of tissue or cell type 
specificity in imprinted genes, meaning not all known 
imprinted genes show ASM throughout the somatic cell 
lineage, as is traditionally assumed [55]. Studies have 
reported tissue and cell type-specific allelic expression 
[56, 57] and tissue-specific ASM [23] in known imprinted 
genes, supporting our finding that imprinting is not 
equally maintained in all genes in every tissue and/or cell 
type.
Although the ASMtuple score is able to recover differ-
ent cases of ASM, we acknowledge that there are other 
cases not linked to ASM, such as cellular heterogeneity, 
in which a proportion of reads are fully methylated, and 
the rest are fully unmethylated. With the technology we 
have used (BS-seq), it is very difficult to discern hetero-
geneity from real ASM in some locations, and we believe 
that to identify ASM, single-cell BS-seq (scBS-seq) data 
may become the most suitable high-throughput technol-
ogy. Previous studies have shown the use of scBS-seq to 
detect heterogeneity within a single cell type [58] and cell 
states [59]. However, the accurate detection of methyla-
tion from scBS-seq is still a difficult task, mainly due to 
the extensive DNA damage from the bisulfite treatment. 
There are currently around 21 different protocols to pro-
file single-cell DNA methylation, mostly bisulfite-based, 
each one aiming at improving recovery of CpGs and 
mapping efficiency [60]. However, it has not been estab-
lished how these methods compare to each other, and a 
consistent framework for their data analysis does not 
exist, as is the case for bulk BS-seq protocols. Therefore, 
there is still work ahead to precisely quantify ASM using 
scBS-seq.
Another limitation arises when considering cancerous 
tissue samples, because of high intra-tumor heterogene-
ity of several biological features, including cellular mor-
phology and gene expression [61]. Our method does not 
account for this additional variability, and we recognize 
this as a limitation. However, we believe the ASM scores 
are still robust enough to detect allelic patterns as shown 
by the recovery of the colorectal cancer subtypes in Fig. 6 
and that even changes in cell composition, which would 
also affect DMR detection, can be interesting events to 
understand.
Regarding DAME detection, we offer two strategies 
that differ in the statistical stringency. In our experi-
ence, fewer regions are obtained by permuting the group 
labels, since the FDR control is more conservative. How-
ever, more regions can always be detected by setting the 
K threshold lower, while still controlling the FDR. The 
Cluster-wise correction, or Simes method, is less con-
servative, and therefore can be used as an alternative to 
extract more detection power. This is likely because of 
the global hypothesis tested at each DAME, where at 
least one CpG site in a region is changed.
We applied DAMEfinder to a real dataset to detect 
DAMEs in CIMP and non-CIMP cancers (versus paired 
normal samples). We found that the ASMtuple and 
ASMsnp scores are consistent in describing the CIMP 
status of samples, but as expected, the ASMsnp score was 
dominated by SD-ASM, because its calculation relies on 
the heterozygous SNPs of each sample; paired samples 
thus clustered with each other not by tissue, as observed 
with the ASMtuple score. In addition, ASMtuple typically 
detected more DAMEs, which we attribute to two rea-
sons. First, there are ∼40× more places in the genome 
where ASMtuple can be calculated. Second, because the 
Table 1 DMRs overlapping DAMEs
Hyper- or hypo-methylated DMR refers to the increase or decrease of methylation in cancers in comparison with paired normal samples, while gain or loss of ASM 
refers to whether cancers have more or less allele specificity than paired normal samples
DMR state Total DMRs DMRs with DAMEs DAMEs with DMRs Gain/loss ASM
CIMP Hyper 5040 2171 2789 2694/95
Hypo 1713 114 116 88/28
Non-CIMP Hyper 3187 76 77 61/16
Hypo 10,033 88 88 64/24
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Fig. 8 DAMEs not detected as DMRs. a Two different DAMEs in non-CIMP, the first located in chr9:136,658,255–136,658,387, and the second 
located in chr4:30,723,185-30,724,099. b Two different DAMEs in CIMP, the first in chr14:105,554,096–105,554,445; the second in chr16:21,295,180–
21,295,412. Y-axis corresponds to ASMtuple or methylation. Points correspond to intermediate positions between a pair of CpG sites
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tuple score is a more general calculation, i.e., it quanti-
fies the mixing of methylated and unmethylated reads, 
instead of relying on allele information.
We also compared the DAME detection to a typical 
DMR analysis of the same samples, and found that DMRs 
detected may or may not include DAMEs. Most DMRs 
overlapping DAMEs were hypermethylated in CIMP 
cancers, which led us to conclude that most DAMEs 
reflected gain of ASM from a low methylation baseline. 
This result shows how differential ASM is a more refined 
definition of differential methylation, and can therefore 
provide additional information regarding methylation 
disruptions in disease (or different conditions).
Conclusion
Cytosine methylation restricted to only one allele, i.e., 
ASM, is a particular pattern of methylation that should 
be approached differently than the rest of the human 
methylome. We have designed DAMEfinder to screen for 
ASM and identify regions of differential ASM. The lat-
ter can be viewed as a special case of differential meth-
ylation. Previous studies have quantified ASM within one 
sample; however, to our knowledge, there is no method 
that identifies loss or gain of ASM between conditions. 
DAMEfinder fills this gap. Studying changes in ASM can 
help us understand epigenetic processes in development 
and diseases. To this aim, further studies are necessary 
to associate ASM to allele-specific gene expression and 
to verify whether gain or loss of ASM would affect gene 
dosage and eventually phenotypes.
Methods
The code used to generate the article figures and data 
processing is available from https ://githu b.com/markr 
obins onuzh /allel e_speci ficit y_paper . The R package is 
available from https ://githu b.com/markr obins onuzh /
DAMEfi nder .
Datasets
Colorectal cancer (CRC) dataset
The CRC dataset came from our published study [52] 
describing the progression of a methylation signature 
from pre-cancerous lesions to colorectal cancer tissue in 
two types of CRC. We used 12 samples from 6 patients 
with sporadic cancer (arrayexpress accession number: 
E-MTAB-6949, Table  2). For each sample, DNA from 
both CRC lesion and normal mucosa was bisulfite-
treated and sequenced according the Roche SeqCapEpi 
CpGiant protocol, where only DNA captured by probes 
was sequenced. We analyzed 12 files in total. For details 
on data generation refer to [52].
Blood dataset
We used data generated by the Blueprint Consortium. 
We downloaded raw paired-end fastq files from venous 
blood of 3 healthy females and 3 healthy males (CD14-
positive, CD16-negative classical monocyte, EGA data-
set: EGAD00001002523) (Table 3).
Quality control and mapping
Quality control was done using fastQC (version 0.11.4) 
[62]. The reads were subsequently trimmed using Trim-
Galore! (version 0.4.5) [63]. Reads were mapped to the 
reference genome using bismark (version 0.18.0). Bow-
tie2 (version 2.2.9) was used to map to genome hg19 in 
the CRC dataset, and hg38 in the Blood dataset. Dupli-
cate reads were removed with the deduplicate command 
from bismark. Deduplicated bam files corresponding to 
technical replicates in the Blood dataset were merged 
with samtools merge [64] for each sample.
Table 2 Colorectal cancer sample characteristics
C CRC,  N paired sample of normal mucosa, non-CIMP the mismatch repair gene 
MLH1 normally expressed, CIMP MLH1 silenced by promoter hypermethylation
a Sample ID changed from arrayexpress










N1 76,801,310 3.025 78.06
C1 Non-CIMP F 68,010,696 2.47 61.62
N2 74,815,980 2.97 69.96
C2 CIMP M 62,122,636 2.47 63.16
N3 66,608,688 2.64 63.88
C3 Non-CIMP M 57,828,284 2.28 57.52
N4 66,108,442 2.62 58.61
C4 CIMP M 59,390,888 2.35 61.25
N5 70,070,214 2.56 59.0032
C5 Non-CIMP M 68,575,884 2.50 49.98
N6 59,056,548 2.15 49.52
C6 CIMP F 79,669,532 2.92 71.39
Table 3 Blood data sample characteristics
a Sample ID changed from source




1 M 390,837,942 12.73
2 M 420,368,438 13.70
3 M 305,490,164 9.95
4 F 383,782,378 12.50
5 F 581,667,082 18.86
6 F 572,224,352 18.55
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SNP calling
We extracted heterozygous SNPs from the CRC dataset 
bam files with Bis-SNP (version 1.0.0) [33] by running 
the BisulfiteGenotyper mode with default parameters, 
using the dbSNP (Build150) [65] generated VCF file 
from the NCBI Human Variation Sets (GRCh37p13, last 
modified:07-10-2017).
methtuple
methtuple (version 1.5.3) [41] was used to produce a list 
of unique tuples of size two and the corresponding MM, 
MU, UM, and UU counts where M stands for “methyl-
ated” and U for “unmethylated”. The bam files of each 
sample are those of PE reads and so they were sorted by 
queryname before using methtuple, as the tool demands 
it.
Tuple‑based ASM score
We used γ = 0.5 and ǫ = 0.2 for all analyses, and allowed 
for a maximum distance of 150 base pairs between 
two CpGs in a tuple. Additional file  1: Figure S6 shows 
ASMtuple diagnostic plots for the CRC dataset (and Addi-
tional file 1: Figure S7 with ASMsnp).
ASMtuple score transformation
We apply a square root transformation to the ASMtuple 
score before running limma, to get a more stable mean–
variance relationship.
allelicmeth
allelicmeth (MethPipe version 3.4.3) [34] is a tool that 
also detects ASM for a given sample directly from BS-
seq reads. The tool is part of the MethPipe pipeline 
[66], which does not use standard bam files. We used 
commands from the pipeline to transform our bismark 
bam files from the CRC dataset into mr files, the input 
to allelicmeth. The output is a bed file with p values 
for each pair of CpG sites, reflecting the degree of allele 
specificity.
amrfinder
amrfinder (MethPipe version 3.4.3) [34] also detects 
ASM from the BS-seq reads, however it generates 
regional scores. As with allelicmeth, we transformed 
bismark bam files from the CRC dataset into mr files, 
then ran methstates to generate epiread files, and used 
these to run amrfinder with default parameters. The 

































 , where 1 and 2 are the the first and 
second CpG site in a tuple i. We treated this converted 
score as true allele-specific methylation to test our scores 
at two thresholds: ≥ 0.5 and ≥ 0.8.
We transformed the p values generated by allelicmeth 
and amrfinder with a negative log base 10. We assigned 
the same transformed p values to all CpG tuples included 
in a single amrfinder region.
We also compared to a score based on whether the 
proportion of methylated reads to total number of reads 
deviates from 0.5, but transformed so a value of 0.5 is 
indicative of high ASM, and 1 or 0 is the lowest ASM. 





We used these four metrics to build ROC curves at dif-
ferent read coverages (5–9, 10–49 and ≥ 50) and at dif-
ferent thresholds of ASMsnp , for a single normal mucosa 
sample in the CRC dataset.
As an additional validation, we used the Blood data-
set to obtain the ASMtuple scores from the promoters 
of known imprinted genes reported in [11]. Only gene 
symbols that were traceable with biomaRt [67, 68] were 
included, and genes labelled to be imprinted in placenta 
were removed, as indicated in [69, 70].
t‑statistic calculation
From the limma R package [39], we use lmFit to fit a lin-
ear model for each CpG position, and eBayes to calcu-
late a moderated t-statistic on the transformed ASMtuple 
score, or on the ASMsnp score. For the former, we set the 
median of two CpGs in a tuple as the CpG position of 
that tuple. Transformed ASM scores across samples are 
given as input to lmFit, as well as a design matrix that 
specifies the conditions of the samples of interest. As 
specified in [39, 71], a CpG site-wise or tuple-wise linear 
model is defined as
where for each CpG site or tuple i, we have a vector of 
ASM scores yi and a design matrix X that relates these 
values to some coefficients of interest βi.
In the end, we test for a specific contrast that 
Ho : Cβij = 0.
Smoothing
We group the positions into genomic clusters using the 
clusterMaker function from the bumphunter R pack-
age [40]. Then, we use the loessByCluster function to 
perform loess within each cluster, and obtain β̃ij , our 
smoothed estimate.
(7)E(yi) = Xβi
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FDR control evaluation
We selected 6 samples of normal tissue from the CRC 
dataset and calculated their ASMsnp scores as a baseline 
in the simulation. We divided the samples in 2 groups 
of 3. We generated 1038 clusters of CpGs with the clus-
terMaker function from the bumphunter package, and 
set a maximum distance between CpGs of 100 bp (Addi-
tional file  1: Figure S8). We chose 20% of all clusters to 
be truly differential, and to each of them added effect to 
a number of randomly selected consecutive CpGs. The 
effect size is the same for every chosen CpG per clus-
ter, and is obtained by inverse transform sampling of 
the form F−1
X
(u) = x , where u ∼ Unif(0.35, 0.75) , and 
FX (x) the CDF of Beta(1, 2.5) [47] (Additional file 1: Fig-
ure S9). In addition, for each truly differential cluster, we 
randomly selected the sign of the effect size (positive or 
negative), as well as the group of samples that contains 
the effect size.
We generated 50 of these simulations, and for each 
of them, ran DAMEfinder with the cluster-wise correc-
tion, and the permutation correction (Additional file  1: 
Figure S10 for distributions of null and observed areas) 
with three different K thresholds: 0.2, 0.5, 0.8. We used 
the iCOBRA R package (version 1.12.1) [72] to calculate 
TPR and FDR at different adjusted p value thresholds: 
0.01, 0.05, 0.1.
DMR detection
We identified DMRs with the dmrseq R package (version 
1.5.11) [47] for each cancer subtype. We specified the tis-
sue via the testCovariate parameter (CIMP, non-CIMP 
or normal), and the patient with the adjustCovariate 
parameter. The cutoff parameter (cutoff of the single CpG 
coefficient that is used to discover candidate regions) was 
set as 0.05 and the rest of parameters were set as default.
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